REP. BURR DRUGS/BIOLOGICS REFORM BILL DROPS INFORMATION DISSEMINATION PROVISIONS; AAP OPPOSES OFF-LABEL PROMOTION OF PEDIATRIC INFORMATION BY SPONSORS
Rep. Burr's (R-N.C.) reprise of his 1996 FDA reform bill deletes provisions that would have allowed off-label use information dissemination by sponsors.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth